Cost-Effectiveness Analysis of Pneumococcal Vaccination with the Pneumococcal Polysaccharide NTHi Protein D Conjugate Vaccine in the Philippines

Value in Health Regional Issues

Volumn 3, Issue 1, 2014, Pages 156-166

  Zhang, Xu Hao ^a   Nievera, Maria Carmen ^b   Carlos, Josefina ^c   Lucero, Marilla ^d   Bibera, Gyneth ^b   Atienza, Maria Isabel ^e   Topachevskyi, Oleksandr ^f   Navarro Locsin, Cecilia Gretchen ^e  

^a GlaxoSmithKline Vaccines ^*  (Singapore)

^b GLAXOSMITHKLINE   (United Kingdom)

^c University of the East   (Philippines)

^d RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^e St Luke's Medical Centre   (Philippines)

^f GSK   (Belgium)

Author keywords

Cost effectiveness; PCV13; PHiD CV; Philippines; Vaccination

Indexed keywords

HAEMOPHILUS INFLUENZAE PROTEIN D CONJUGATE VACCINE; HAEMOPHILUS INFLUENZAE VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ACUTE OTITIS MEDIA; ARTICLE; BACTEREMIA; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEALTH CARE UTILIZATION; MASS IMMUNIZATION; MENINGITIS; MORTALITY; PHILIPPINES; PNEUMONIA; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

EID: 84901237732     PISSN: 22121099     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vhri.2014.04.004     Document Type: Article

References (49)

1. Pneumococcal conjugate vaccine for childhood immunization: WHO position paper [in English, French]. Wkly Epidemiol Rec 2007, 82:93-104.
2. Santos J, Madrid MAC, Banez MAP, et al. Active hospital-based epidemiological surveillance of invasive pneumococcal disease (IPD) in children in Metro, Manila, Philippines. Presented at: 7th ISPPD. Tel Aviv, Israel, March 14-18, 2010.
3. Lucero MG, Nohynek HM, Nillos LT, et al. AOM in Filipino children with pneumonia: a nested study within an efficacy trial of 11-valent pneumococcal conjugate vaccine in Bohol, Philippines. Presented at: 7th ISPPD. Tel Aviv, Israel, March 14-18, 2010.
4. Caro RM, Llanes EGDV, Ricalde RC. Prevalence of clinically diagnosed acute otitis media (AOM) in the Philippines: a national survey. Presented at: WSPID. Melbourne, Australia, November 16-19, 2011.
5. Acuin J. Chronic Suppurative Otitis Media: Burden of Illness and Management Options 2004, World Health Organization, Geneva, Switzerland.
6. Summary of Product Characteristics: Synflorix Suspension for Injection in Pre-Filled Syringe 2012, GlaxoSmithKline, GlaxoSmithKline, Uxbridge, Middlesex, UK.
7. Pfizer/Wyeth. Prevnar 13 full prescribing information. 2012. Available from:. [Accessed May 05, 2014]. http://labeling.pfizer.com/showlabeling.aspx?id=501.
8. Transferability of economic evaluations across jurisdictions. Available from:. [Accessed May 05, 2014]. http://www.ispor.org/councils/documents/ISPOR_Report_Good_Practices_Econ_Data_Transferability0308.pdf.
9. By A., Sobocki P., Forsgren A., Silfverdal S.A. Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model. Clin Ther 2012, 34:177-189.
10. Robberstad B., Frostad C.R., Akselsen P.E., et al. Economic evaluation of second generation pneumococcal conjugate vaccines in Norway. Vaccine 2011, 29:8564-8574.
11. FIield Health Service Information System. FIield Health Service Information System (FHSIS) Annual Report 2010. Manila, Philippines: National Epidemiology Center, Department of Health, 2010.
12. Knerer G., Ismaila A., Pearce D. Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise. J Med Econ 2012, 15:61-76.
13. Sonnenberg F.A., Beck J.R. Markov models in medical decision making: a practical guide. Med Decis Making 1993, 13:322-338.
14. Gross national income & gross domestic product. Available from:. [Accessed May 5, 2014]. http://www.nscb.gov.ph/sna/2012/1st2012/2012per1.asp.
15. Edmond K., Clark A., Korczak V.S., et al. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2010, 10:317-328.
16. Maimaiti N., Aljunid S., Ahmed Z., et al. Clinical burden of pneumococcal diseases in Malaysia. Presented at: 14th Asia-Pacific Congress for Pediatrics. Kuching, Malaysia, September 8-12, 2012.
17. Yu V.L., Chiou C.C., Feldman C., et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003, 37:230-237.
18. Feigin R.D., Cherry J.D. Feign and Cherry's Textbook of Pediatric Infectious Diseases 2009, Saunders, Philadelphia, PA. 6th ed.
19. Epidemiology and Prevention of Vaccine-Preventable Diseases. Public Health Foundation 2012, Centers for Disease Control and Prevention.
20. Chang CJ, Wang PC, Huang YC, Wu BS. Economic and clinical burden of pneumococcal diseases and acute otitis media in Taiwan: a nationwide population-based database analysis. Presented at: ISPOR 4th Asia-Pacific Conference. Phuket, Thailand, September 5-7, 2010.
21. Lupisan S.P., Ruutu P., Abucejo-Ladesma P.E., et al. Central nervous system infection is an important cause of death in underfives hospitalised with World Health Organization (WHO) defined severe and very severe pneumonia. Vaccine 2007, 25:2437-2444.
22. Whitney C.G., Pilishvili T., Farley M.M., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006, 368:1495-1502.
23. Butler J.C., Breiman R.F., Campbell J.F., et al. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. JAMA 1993, 270:1826-1831.
24. Singleton R.J., Butler J.C., Bulkow L.R., et al. Invasive pneumococcal disease epidemiology and effectiveness of 23-valent pneumococcal polysaccharide vaccine in Alaska native adults. Vaccine 2007, 25:2288-2295.
25. Miller E., Andrews N.J., Waight P.A., et al. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 2011, 29:9127-9131.
26. Andrews N., Miller E., Kaye P., et al. Effectiveness of the 13 valent pneumococcal conjugate vaccine against invasive pneumococcal disease (IPD) in England and Wales. Presented at: 8th International Symposium on Pnumococci and Pneumococcal Diseases. Iguacu Falls, Brazil. March 11-15, 2012.
27. Dagan R., Patterson S., Juergens C., et al. Efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in preventing nasopharyngeal colonization with PCV7-serotypes: a randomized double-blind trial. Presented at: 8th International Symposium on Pnumococci and Pneumococcal Diseases. Iguacu Falls, Brazil, March 11-15, 2012.
28. Cohen R., Levy C., Bingen E., et al. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Ped Infect Dis J 2012, 31:297-301.
29. Pneumococcal sub-committee of Joint Committee on Vaccination and Immunisation: minute of meeting on Wednesday 30 May 2012. Available from:. [Accessed May 05, 2014]. http://media.dh.gov.uk/network/261/files/2012/07/JCVI-minutes-Pneumococcal-sub-committee-meeting-held-on-30-May-2012.pdf.
30. Tregnaghi MW, Sáez-Llorens X, López P, et al. Evaluating the efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHID-CV) against community-acquired pneumonia in Latin America. Presented at: 29th Annual Meeting of the European Society for Paediatric Infectious Diseases. The Hague, The Netherlands, June 7-11, 2011.
31. Cutts F.T., Zaman S.M., Enwere G., et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005, 365:1139-1146.
32. COMPAS Group. Design/setting of COMPAS: Latin-American trial evaluating the efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV). Presented at: 29th Annual Meeting of the European Society for Paediatric Infectious Diseases. The Hague, The Netherlands, June 7-11 2011.
33. Hansen J., Black S., Shinefield H., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Ped Infect Dis J 2006, 25:779-781.
34. Klugman K.P., Madhi S.A., Huebner R.E., et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003, 349:1341-1348.
35. Lucero M.G., Nohynek H., Williams G., et al. Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial. Ped Infect Dis J 2009, 28:455-462.
36. Madhi S.A., Kuwanda L., Cutland C., Klugman K.P. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin Infect Dis 2005, 40:1511-1518.
37. Prymula R., Peeters P., Chrobok V., et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006, 367:740-748.
38. Eskola J., Ward J., Dagan R., et al. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 1999, 354:2063-2068.
39. Bennett J.E., Sumner W., Downs S.M., Jaffe D.M. Parents' utilities for outcomes of occult bacteremia. Arch Pediatr Adolesc Med 2000, 154:43-48.
40. Oh P.I., Maerov P., Pritchard D., et al. A cost-utility analysis of second-line antibiotics in the treatment of acute otitis media in children. Clin Ther 1996, 18:160-182.
41. Morrow A., De Wals P., Petit G., et al. The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine. Can J Infect Dis Med Microbiol 2007, 18:121-127.
42. Navarro-Locsin CG. Economic cost of OM in the Phil. Presented at: 6th Extraordinary International Symposium on Recent Advances in Otitis Media. Seoul, South Korea, May 6-10, 2009.
43. Talbird S.E., Taylor T.N., Caporale J., et al. Residual economic burden of Streptococcus pneumoniae- and nontypeable Haemophilus influenzae-associated disease following vaccination with PCV-7: a multicountry analysis. Vaccine 2010, 28(Suppl. 6):G14-G22.
44. UK Pneumococcal Weekly Surveillance. Available from:. [Accessed May 5, 2014]. http://www.Hpa.Org.Uk/Topics/InfectiousDiseases/InfectionsAZ/Pneumococcal/EpidemiologicalDataPneumococcal/CurrentEpidemiologyPneumococcal/.
45. Jokinen J, Rinta-Kokko H, Siira L, et al. Indirect impact of 10-valent pneumococcal conjugate vaccine against invasive pneumococcal disease IPD among unvaccinated children in Finland. Presented at: 31st Annual Meeting of European Society of Paediatric Infectious Diseases. Milan, Italy, May 28-June 1, 2013.
46. Kilpi T, Palmu AA, Ruokokoski E, et al. Indirect impact of Pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHID-CV10) on invasive pneumococcal disease (IPD) in a clinical trial. Presented at: 8th World Congress on Pediatric Infectious Diseases (WSPID). Cape Town, South Africa, November 19-22, 2013.
47. Dagan R., Greenberg D., Jacobs M.R., Phillips B.L. Pneumococcal infections. Feigin and Cherry's Textbook of Pediatric Infectious Diseases 2009, Elsevier Health Sciences, Philadelphia. 6th ed. R.D. Feigin, J. Cherry, G.J. Demmler-Harrison, S.L. Kaplan (Eds.).
48. Republic of The Philippines. 2010 census of population and housing highlights. Available from:. [Accessed May 5, 2014]. http://www.census.gov.ph/statistics/census/population-and-housing.
49. Philippine Health Insurance Corporation: 2011 stats & charts. Available from: [Accessed May 5, 2014]. http://www.philhealth.gov.ph/about_us/statsncharts/snc2011.pdf.